On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly diagnosed standard-risk B-cell ALL who had an average or high risk of relapse. The study, which was stopped early due to its significant benefits, showed that:
✅ 3-year disease-free survival improved to 96.0% with blinatumomab + chemotherapy vs. 87.9% with chemotherapy alone.
✅ Patients with an average relapse risk had a survival rate of 97.5% (vs. 90.2% with chemotherapy alone).
✅ Patients with a high relapse risk had a survival rate of 94.1% (vs. 84.8% with chemotherapy alone).
✅ The treatment was well-tolerated, with rare cases of grade 3 or higher cytokine release syndrome, seizures, or sepsis.
These findings reinforce blinatumomab as a powerful addition to treatment strategies for childhood B-cell ALL, offering a significantly improved survival rate and potentially changing the standard of care.
Read more: https://lnkd.in/eFbXU3VV.).
A huge thanks to all the researchers, clinicians, and patients who made this study possible!
